NCT03283696 2020-09-10
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
Eli Lilly and Company
Eli Lilly and Company
Merck Sharp & Dohme LLC
Children's Oncology Group